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Research
AbstrACt
background Asthma is seasonal with peaks in 
exacerbation rates in school-age children associated with 
the return to school following the summer vacation. A drop 
in prescription collection in August is associated with an 
increase in the number of unscheduled contacts after the 
school return.
Objective To assess whether a public health intervention 
delivered in general practice reduced unscheduled medical 
contacts in children with asthma.
Design Cluster randomised trial with trial-based 
economic evaluation. Randomisation was at general 
practice level, stratiied by size of practice. The 
intervention group received a letter from their general 
practitioner (GP) in late July outlining the importance of (re)
taking asthma medication before the return to school. The 
control group was usual care.
setting General practices in England and Wales.
Participants 12 179 school-age children in 142 general 
practices (70 randomised to intervention).
Main outcome Proportion of children aged 5–16 years 
who had an unscheduled contact in September. Secondary 
endpoints included collection of prescriptions in August 
and medical contacts over 12 months (September–
August). Economic endpoints were quality-adjusted life-
years gained and health service costs.
results There was no evidence of effect (OR 1.09; 95% CI 
0.96 to 1.25 against treatment) on unscheduled contacts 
in September. The intervention increased the proportion 
of children collecting a prescription in August by 4% 
(OR 1.43; 95% CI 1.24 to 1.64). The intervention also 
reduced the total number of medical contacts between 
September–August by 5% (incidence ratio 0.95; 95% CI 
0.91 to 0.99). The mean reduction in medical contacts 
informed the health economics analyses. The intervention 
was estimated to save £36.07 per patient, with a high 
probability (96.3%) of being cost-saving.
Conclusions The intervention succeeded in increasing 
children collecting prescriptions. It did not reduce 
unscheduled care in September (the primary outcome), but 
in the year following the intervention, it reduced the total 
number of medical contacts.
trial registration number ISRCTN03000938; Results.
IntrODuCtIOn 
Asthma episodes and deaths are known to be 
seasonal.1 A number of reports have shown 
peaks in asthma episodes in school-age chil-
dren associated with the return to school 
following the summer vacation.2–10 Chil-
dren returning to school are exposed to a 
variety of novel respiratory insults including 
allergens and viruses, at a time of changing 
climactic conditions. It has previously been 
shown that viral infection and allergen expo-
sure in allergen-sensitised asthmatics are 
strengths and limitations of this study
 Ź The evaluation was a highly eficient study design 
using routine data to evaluate a general practice 
public health intervention designed with children 
with asthma and their parents.
 Ź The intervention was simple to implement, had good 
user acceptability and was cost saving.
 Ź The intervention increased prescription uptake in 
the month prior to the return to school with 30% 
more prescriptions collected.
 Ź There was no immediate effect in September, but in 
the wider time intervals of September to December 
and September to August, there was evidence of ef-
fect with a reduction in the mean number of medical 
contacts.
 Ź The coding of the outcomes from the routine data 
was challenging and the assessment of adherence 
was not possible.
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associated with increased hospital admissions for acute 
asthma.11 
Our previous research12 confirmed the increase in 
unscheduled medical contacts with children with asthma 
being approximately twice as likely as controls to have an 
unscheduled medical contact with their doctor around 
the time of the return back to school. In the same study, 
it was found that in August, immediately preceding the 
return back to school, there were 25% fewer prescrip-
tions for inhaled corticosteroids, compared with July 
and September. Patients who received a prescription 
for inhaled corticosteroids were less likely to have an 
unscheduled medical contact after the return to school.
Little is known about the factors that are associated 
with the drop in prescriptions in August. Research on 
adherence to paediatric asthma treatment in general 
has identified weak beliefs about the necessity of asthma 
medication as a key reason for non-adherence.13 Given 
that asthma symptoms decline in the summer months, 
this may lead to weaker beliefs about the necessity to 
take asthma medication. The general practitioner (GP) 
letter was designed to address this belief by emphasising 
the importance of (re)taking asthma mediation prior to 
returning to school.
The current study is a cluster randomised trial to eval-
uate whether a letter sent from a GP at the start of the 
summer vacation reminding parents of children with 
asthma of the necessity of taking their asthma medication 
before the return back to school. The study evaluated 
whether the letter reduced unscheduled contacts after 
the return back to school and increased prescriptions in 
August.
reseArCh AIMs AnD ObjeCtIves
The aim of the study was to assess if a general practice 
delivered public health intervention (a letter sent from 
the GP to parents/carers of school-age children with 
asthma) can reduce the number of unscheduled medical 
contacts per child after the school return.
MethODs
study design
The study was an open-label cluster randomised trial 
where GP practices were randomised to the intervention 
or usual care. The study protocol and Health Technology 
Assessment (HTA) report have been published.14 15 The 
effectiveness of the intervention was assessed on the 
basis of reduced unscheduled medical contacts after the 
return to school in September and prescription uptake 
prior in August. The primary study period was 1–30 
September 2013 after the return to school. The extended 
study period was 1 September–31 December 2013, since 
asthma-related appointments are more frequent in these 
months for children with asthma. The full follow-up 
period was 12 calendar months from 1 September 2013 
to 31 August 2014. Prescription uptake and scheduled 
medical contacts such as asthma reviews were evaluated 
during the periods August 2013 and August 2013–July 
2014, respectively.
A cluster randomised trial was chosen due to the nature 
of the condition of asthma. Even if the study design was 
individually randomised, there would have been a need 
for the study to be randomised by household as siblings 
are likely to have asthma. A further consideration was 
that we wished for the intervention to represent possible 
routine care for future implementation. A practice level 
intervention would represent this.
The health economic analyses were based on a 
12-month period from 1 August 2013 to 31 July 2014. 
The period starts a month earlier than the evaluation of 
medical contacts in order to incorporate the cost asso-
ciated with delivering the intervention including any 
increase in prescriptions or medical contacts in response 
to the intervention that occurred during August 2013.
The primary outcome was the proportion of patients 
who had an unscheduled medical contact in September 
2013.
The secondary outcomes evaluated included the 
number of unscheduled medical contacts in September 
2013 and the number and proportion of any medical 
contacts (scheduled and unscheduled) in the same 
time interval as well as in the time intervals September–
December 2013 and September 2013–August 2014. The 
analyses of the same outcomes were repeated for the 
other time intervals.
Participants
Participants were school-age children with asthma, aged 
between 4 years and 16 years, registered with a GP. The 
primary analysis population was the intention-to-treat 
population (ITT) among children aged between 5 years 
and 16 years of age.
The choice of the age group of 5–16 years as the primary 
analysis population is due to the difficulty associated with 
making a diagnosis of asthma among children below 
this age.16 17 Patients aged 4–5 years were analysed sepa-
rately to those aged 5–16 years and are not included in 
this paper. Additional analyses were restricted specifically 
to children who had received a prescription for steroid 
inhalers in the previous year.
Interventions
Sites were randomly allocated to either: intervention 
group: sending out the letter, or control group: standard 
care (no letter).
The intervention was a letter sent from a GP to the 
parents/carers of children with asthma reminding them 
to maintain their children’s medication and collect 
a prescription if they were running low (see online 
supplementary appendix 1). It also advised that should 
their child have stopped their medication, it should be 
resumed as soon as possible.
The letter template was developed based on stan-
dard letters already used in general practice and 
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designed to address beliefs about the necessity of 
taking asthma medication before the return back to 
school. The wording of the letter had input from the 
study team, which includes a GP, health psychologist 
and consultant respiratory paediatrician. The letter 
was also discussed in detail at two patient and public 
events that included school-age children with asthma 
and their parents.18–20
The intervention letters were sent out the week 
commencing 29 July 2013 to obviate the distraction 
of planning for family holidays and yet leave enough 
time for parents and children to renew prescriptions 
and gain benefit from the medication. The letter and 
the timing of the letter was decided following discus-
sion with the patients and public involvement (PPI) 
group.19
Patient involvement
There were three PPI consultation events with children 
with asthma and their parents. The first consultation 
event was funded by a grant by National Institute of 
Health Research (NIHR) Research Design Service for 
Yorkshire and the Humber prior to submission of the 
grant application in January 2011.
At this first consultation event, it was agreed that a letter 
from their practice would be a useful reminder and not 
seen in any way as intrusive. A draft of the proposed letter 
was reviewed, and the children fed back that they believed 
that the letter from their GP should be addressed to their 
parents rather than to themselves.
The second PPI consultation event was held after 
the grant was awarded in September 2012.19 At this 
meeting, the intervention letter was finalised. The 
general feeling among the group was that the inter-
vention did not adequately reflect the seriousness of 
asthma as a health condition. It was felt therefore 
that there was a danger that the intervention could be 
ignored by parents or that the information it contained 
could be forgotten. The letter was amended to reflect 
this input.
The consultation event also discussed the timing of the 
intervention, and it was proposed to send the interven-
tion the first week of August. The event also reviewed the 
lay summary for the study and provided input to the logo 
for the study.
Two parents also agreed to join the TSC for the study. 
At the first TSC meeting, it was agreed to bring the timing 
of the intervention forward by a week to the end of July, 
as asthma medication has a better chance of working the 
earlier it is used consistently.
A third PPI consultation event was held after the study 
had been completed that will be discussed in the Discus-
sion.21 There is a website where the PPI events are detailed 
(http://www. sheffield. ac. uk/ scharr/ sections/ dts/ ctru/ 
pleasant/ ppi, assessed 8 December 2017). There has also 
been a separate publication on the first two PPI consulta-
tion events.20
ethical approval and research governance
National Health Service permissions to conduct the study 
was obtained for all the primary care trusts in England 
and health boards in Wales.
Details of an amendment to the protocol are given in 
online supplementary appendix 2. The amendment was 
to extend the follow-up period by 1 month to the end of 
September 2014.
The trial was registered with the International Standard 
Randomised Controlled Trial Register (ISRCTN) refer-
ence number ISRCTN 03000938.
setting
The setting was primary care with the unit of cluster 
being general practices. Site eligibility required practices 
to be using the Vision IT software and be part of Clin-
ical Practice Research Datalink (CPRD). Site recruitment 
was conducted by CPRD and the NIHR Primary Care 
Research Network with the Preventing and Lessening 
Exacerbations of Asthma in School-age children Associ-
ated with a New Term (PLEASANT) study team.22
CPrD recruitment
A practice recruitment pack, consisting of a detailed study 
information sheet and an expression of interest form, 
was sent to all 433 practices contributing to CPRD in 
England and Wales at the time of recruitment.22 Practices 
were also recruited through the primary care research 
network. Recruitment took place over a 7-month period 
from January 2013 to July 2013. For these practices to be 
in the trial, they needed to join the CPRD.
randomisation and blinding
After each practice gave verbal consent to participate 
in the trial, they were randomised to either the inter-
vention or usual care.22 Randomisation was stratified by 
size of general practice (ie, the ‘list size’) to ensure that 
there was an equal sample size—in terms of number of 
school-age children with asthma—in each arm of the trial. 
The randomisation sequence was generated by a statisti-
cian based within the Sheffield Clinical Trials Research 
Unit (CTRU), using a blocked randomisation and allo-
cation concealment was ensured by restricting access to 
the two CTRU statisticians. Once practices had agreed 
to participate, their identifier and list size was forwarded 
to the trial statistician for randomisation to one of the 
two groups. The randomisation was then revealed to the 
study manager and research assistant. The study team 
were unblinded throughout the study but had no access 
to data until after a statistical analysis plan was developed 
and had no influence on data capture.
Data management
Data were collected through the CPRD, which captures 
the coding for each consultation by staff in the practice. 
The medical consultations and diagnostic codes were 
reviewed to determine if each contact was a scheduled 
contact, such as a medicines review, or an unscheduled 
contact, such as an acute or an out of hours visit.
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An independent GP adjudication panel was estab-
lished to help in the coding. The adjudication panel 
met three times and did not have access to the rando-
misation group when reviewing the data. The adjudica-
tion panel reviewed and coded 4600 unique terms into 
scheduled and unscheduled medical contacts. These 
terms accounted for 92% of all medical contacts, but 17% 
of all terms were used in the study. Terms not coded by 
the adjudication panel were coded as unscheduled. In 
addition, 7.9% of all contacts did not have any terms to 
indicate consultation type or diagnosis, and free text was 
used in the database system to which the study team had 
no access. The adjudication panel advised to code these 
contacts as unscheduled.
statistical methods
Analysis populations
The study was designed to detect a difference of 5% in the 
proportion of children who have an unscheduled medical 
contact (30% vs 25%) with 90% power and two-sided 
significance level of 5%, with an intraclass correlation 
(ICC) of 0.03 to account for clustering. Based on this, we 
estimated that we required 70 practices per arm. It was 
anticipated that the sample size of 140 practices would 
equate to approximately 14 000 school-age children with 
asthma. We assumed equal cluster sizes in the sample size 
calculation. Sensitivity analyses indicated that the study 
was robust to the assumptions made for the ICC as well 
as to practices not sending the intervention and reducing 
the observed effect size.15
Each of the outcomes were evaluated on for each of each 
subpopulations: children aged 5–16 years (the primary 
analysis population) and children aged 5–16 years who 
have prescriptions for steroid preventers. The analyses 
were restricted specifically to children who had received 
a prescription for preventer inhalers in the previous year 
as this was intended to identify the treatment effect in the 
population likely to receive most benefit.
The primary analyses of effectiveness were performed 
on the ITT population. Analyses were also conducted on 
the per protocol (PP) population. The health economic 
analyses were based on the PP population. ITT analyses 
comprised all practices for whom data were obtained for 
the study period (see number of participants and analysis 
subsets). There were two criteria for exclusion from PP 
analyses. First, for practices that did not send intervention 
as requested the entire practice data were excluded from 
PP analyses. Second, individual children who were not 
sent the intervention letter. GPs were given discretion to 
withhold the letter from any children they believed were 
unsuitable. In such cases, the individual was excluded 
from PP analyses.
Analytical methods
The proportion of children having an unscheduled 
medical contact was analysed separately for each time 
period using logistic regression with the individual’s 
age, sex, number of contacts the previous September 
as covariates, the trial arm (intervention or control) as 
a fixed effect and the design/cluster effect of general 
practice as a random effect. The proportion of children 
having a prescription within each time period was anal-
ysed in the same manner. The number of unscheduled 
medical contacts made in each period by the children as 
well as the number of prescriptions ordered within a time 
period was both analysed using a random effects negative 
binomial model in which the same covariates as above 
were included.15
health economic methods
An economic evaluation was undertaken to compare the 
incremental cost per quality-adjusted life-year (QALY) of 
the reminder letter versus standard care. The perspective 
of the analysis was that of the NHS (primary and secondary 
care resource use based on available CPRD data and asso-
ciated costs). We assumed the intervention would have 
no impact on mortality or quality of life (utility) beyond 
4 months, and as a result, QALYs were calculated for the 
4-month postintervention time period. Costs were calcu-
lated for 1-year postintervention to allow for changes in 
the timing of routine asthma care in response to the inter-
vention to be distinguished from changes in the number 
of scheduled contacts.
Bootstrapped costs were evaluated 12-month postin-
tervention with 1-year linear regression-based baseline 
adjustment (BA). Costs for the letter intervention were 
based on a survey of participating practices that included 
questions on staff members involved as well as staff time.23 
Full details of the methods used in the economic analysis 
have been published in a separate paper.24
trial oversight
A trial steering committee (TSC) was established to give 
oversight to the study. The TSC consisted of an indepen-
dent chair (GP), two independent members (academic 
GP and statistician) and two lay members (parents of chil-
dren with asthma) along with the principal investigator 
and key staff within the CTRU (as non-voting members). 
The role of the TSC was to provide supervision of the 
protocol and statistical analysis plan and to provide advice 
on, and monitor progress of, the trial.
trIAl results
recruitment and participant low
The target sample size was 140 GP practices. In total, 142 
practices agreed to take part in the study. Recruitment 
of GP practices was undertaken over a 7-month period, 
details of which have been published.22 Of these prac-
tices, one (a control group practice with 99 children with 
asthma) withdrew consent after the start of the study for 
the data to be extracted and stored by the CPRD (inde-
pendent of the study); this practice was excluded from all 
analyses. In total, 70 practices (comprising 5917 individ-
uals) were randomised to the intervention (letter) and 71 
practices (6262 individuals) to control. The Consolidated 
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Standards of Reporting Trials (CONSORT) diagram is 
given in figure 1 for the 12-month follow-up of the study.
baseline characteristics
The descriptive statistics of the 12 179 subjects and 141 
practices are included in table 1A and B. Summaries 
reported are stratified by intervention type and overall.
number of participants and analysis subsets
For each study period, analyses were based only on prac-
tices that contributed data to the entirety of that period. 
In other words, if practices stopped submitting data to 
CPRD before the end of a given follow-up period, they were 
excluded from all analyses for that time period. Practices 
that changed their software from the Vision IT system were 
no longer able to participate in CPRD and so withdrew 
from the study. The data from the practices until the time 
they withdrew was included in the statistical analysis. Details 
of the practices within the study during each time period 
are given in online supplementary appendix 3.
Figure 1 shows the flow of patients and practices for 
the primary analysis population (aged 5–16 years). Of the 
456 practices invited, 433 were through the CPRD and 
23 were through the primary care research network and 
joined the CPRD.22
There were 786 GP exclusions in the intervention arm. 
There were zero GP exclusions in the control arm, as it 
Figure 1 CONSORT diagram. 
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was impossible for the GPs to exclude individuals from 
receiving letters when no patients in the control arm were 
due to receive a letter.
Clinical results
The primary time point for the analysis was September. 
Thus, in the primary analysis the proportion of individ-
uals who had at least one unscheduled medical contact in 
September was 45.2% in the intervention arm, compared 
with 43.7% in the control arm (adjusted OR=1.09, 95% CI 
0.96 to 1.25) (see table 2A). The ICC for the primary anal-
ysis was 0.026 and was consistent with the estimate for the 
sample size calculation. In terms of mean contacts the 
number of unscheduled contacts are comparable (inci-
dence rate ratio (IRR)=1.02 95% CI 0.94 to 1.12). The 
results are comparable for children receiving preventer 
medication (see table 2B).
In the year following the intervention, there was evidence 
of a reduction in the mean number of medical contacts. 
As a consequence, the incidence ratio declines as longer 
time periods are analysed (see table 2A), suggesting that 
the short-term increase in medical contacts in September 
is gradually outweighed by decreases in unscheduled 
contacts in the longer term. There is a non-statisti-
cally significant 3% reduction in unscheduled contacts 
(IRR=0.97 with 95% CI 0.95 to 1.04), and a statistically 
significant 5% reduction in the total number of medical 
contacts (IRR=0.95 with 95% CI 0.91 to 0.99), over the 12 
months following the intervention.
Unscheduled medical contacts for children in the trial 
in the year before and after the intervention are presented 
in figure 2A. A pronounced drop in unscheduled medical 
contacts can be seen in August 2012. After the return to 
school in September 2012 there is an increase in unsched-
uled medical contacts which peaks in October/November 
before reducing.
In 2013, there is a similar pattern to 2012 in the control 
arm. In contrast, in the intervention arm, although 
there is no immediate effect of the intervention in 
September, however, the peak in October/November is 
less pronounced than in the control arm.
The planned analysis was of prescriptions in August. 
This demonstrated that the intervention (letter) was asso-
ciated with a statistically significant increase in the uptake 
of prescriptions in the month of August 2013 (see table 3). 
In August, 876 (16.5%) patients in the intervention arm 
had at least one prescription compared with 703 (12.6%) 
in the control group (adjusted OR 1.43, 95% CI 1.24 to 
1.64); the total number of prescriptions was also higher 
(adjusted IRR 1.31, 95% CI 1.17 to 1.48). In line with the 
increase in prescriptions, there was also a non-statistically 
Table 1 Descriptive statistics of patients and surgeries
(A) Descriptive statistics of sex (frequencies and percentages reported) and age (mean, SD, median, IQR and range 
reported). Statistics produced at subject level. 
Variable Letter (n=5917) No letter (n=6262) Total (n=12 179)
Sex 
  Male, n (%) 3505 (59.24) 3749 (59.87) 7254 (59.56) 
  Female, n (%) 2412 (40.76) 2513 (40.13) 4925 (40.44) 
Age
  Mean (SD) 10.51 (3.29) 10.55 (3.30) 10.53 (3.30) 
  Median (IQR) 10.80 (7.88–15.97) 10.89 (7.80–15.97) 10.89 (7.80–15.97) 
  Range 4.05–15.97 4.05–15.97 4.05–15.97 
Unscheduled contacts: September 2012 
  Mean (SD) 0.84 (1.20) 0.88 (1.26) 0.86 (1.23) 
  Median (IQR) 0.00 (0.00–1.00) 0.00 (0.00–1.00) 0.00 (0.00–1.00) 
  Range 0.00–10.00 0.00–12.00 12.00
Unscheduled contacts: September–December 2012 
  Mean (SD) 3.65 (3.34) 3.78 (3.66) 3.71 (3.51) 
  Median (IQR) 3.00 (1.00–5.00) 3.00 (1.00–5.00) 3.00 (1.00–5.00) 
  Range 0.00–31.00 0.00–51.00 0.0 51.00 
(B) Descriptive statistics of size (mean, SD, median, IQR and range reported). Statistics produced at surgery level. 
Variable Letter (n=70) No letter (n=71) Total (n=141)
Size 
  Mean (SD) 85 (44) 88 (64) 86 (55) 
  Median 80 (49–114) 75 (41–107) 76 (45–113) 
  Range 4–209 10–293 4–293 
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significant increase in scheduled contacts made in August 
2013, in terms of having at least one contact (adjusted 
OR 1.13, 95% CI 0.84 to 1.52) and a statistically signifi-
cant increase in terms of the mean number of scheduled 
contacts (IRR=1.17, 95% CI 1.06 to 1.29).
Preventer prescription collections for children in 
the trial in the year before and after the intervention 
are presented in figure 2B. Mirroring the unscheduled 
contacts in August 2012, there is a reduction in prescrip-
tions collected in this month. After the return to school 
in September, there is an increase in prescriptions 
collected with a peak in the interval between October and 
December followed by a reduction.
In 2013, there is a similar pattern to 2012 in the 
control arm. In contrast, in the intervention arm, there 
is a marked increase in prescriptions in August 2013 that 
appears to continue into September before declining.
Per-protocol population analyses were also conducted, 
with the results being broadly consistent with the inten-
tion-to-treat analyses reported above. However, there 
were larger effects for the increase in scheduled contacts 
and uptake of prescriptions in August but smaller effects 
for unscheduled contacts and total medical contacts.14
The analysis of respiratory relation contacts is given in 
online supplementary appendix 4 and figure 3.
health economic results
The full results of the economic evaluation have been 
published in a separate paper so only key baseline adjusted 
(BA) base case results are provided here.24 The average 
cost per child of sending the intervention was £1.34 per 
child. The fall in medical contacts over 1 year described in 
the clinical results led through into the health economic 
assessment. A mean reduction in costs per child of £36.07 
was estimated, and there was 96.3% certainty of the inter-
vention being cost saving. The economic evaluation esti-
mated a mean QALY loss of 0.00017, which is practically 
zero.
DIsCussIOn
Previous work has shown an increase in the number of 
unscheduled medical contacts by children in autumn 
months (September–December), which may be due to 
the start of the new school term.12 By sending a letter at 
the start of the school holidays to remind children of the 
importance of taking their medication, it was hypothe-
sised that this increase in unscheduled medical contacts 
may be averted. More specifically, it was predicted that 
a reminder letter would lead to a greater uptake of 
inhaler prescriptions in August that, in turn, would lead 
to increased adherence and, finally, fewer unscheduled 
medical appointments after the return to school.
There was evidence of an impact on the first part of 
this pathway as the intervention group demonstrated a 
higher uptake of prescriptions in August 2013. They also 
had a non-statistically significant increase in the number 
of scheduled contacts in the same month.
Data are not available to confirm actual medicine usage 
and, as a result, it is unclear whether the increased uptake 
also translated into an increased usage. The original plan 
was to assess this through the medication possession ratio, 
which estimates the time a child has collected medication 
for over the time the child should have collected time 
Table 2 Analysis of unscheduled and total medical contacts
Time period
Treatment arm* Treatment arm*
Intervention 
(%)
Control
(%) OR† 95% CI
Intervention
(mean)
Control
(mean)
Incidence 
ratio† 95% CI
(A) For all children in the intention-to-treat population 
  Unscheduled September 45.2 43.7 1.09 0.96 to 1.25 0.81 0.81 1.02 0.94 to 1.12
  Contacts September–December 80.1 79.1 1.10 0.96 to 1.26 3.19 3.32 0.98 0.93 to 1.04
September–August 93.1 93.3 0.97 0.82 to 1.15 9.08 9.37 0.97 0.95 to 1.04
  Total September 57.8 58.4 0.99 0.80 to 1.22 1.05 1.10 0.97 0.87 to 1.07
  Contacts September–December 89.3 88.4 1.06 0.89 to 1.27 4.31 4.43 0.95 0.90 to 1.02
September–August 96.6 96.4 0.89 0.71 to 1.12 11.52 12.08 0.95 0.91 to 0.99
(B) For children receiving preventer medication in the intent to treat population 
  Unscheduled September 46.3 45.4 1.07 0.94 to 1.23 0.83 0.84 1.01 0.92 to 1.10
  Contacts September–December 81.3 81.4 1.04 0.90 to 1.21 3.27 3.44 0.97 0.92 to 1.03
September–August 93.9 94.6 0.84 0.69 to 1.02 9.31 9.71 0.98 0.92 to 1.14
  Total September 59.1 60.4 0.97 0.79 to 1.21 1.08 1.14 0.96 0.86 to 1.07
  Contacts September–December 90.4 90.5 0.98 0.81 to 1.19 4.43 4.70 0.95 0.89 to 1.01
September–August 97.1 97.3 0.81 0.64 to 1.01 11.82 12.53 0.96 0.90 to 1.12
*The proportions and means are simple summary statistics.
†The ORs and incidence ratios with the corresponding CIs are from a formal statistical analysis allowing for covariates and the effect 
of clustering. 
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for. However, this could not be estimated for these data 
due to inadequate recording of prescription data in the 
routine data. Further work is required to determine how 
to assess adherence using such routine data.
The primary endpoint was unscheduled medical 
contacts in September 2013, which coincided with the 
start of the new school term. There was no evidence of 
a reduction in the intervention group. In fact, there was 
a non-statistically significant increase in the proportion 
of children who had an unscheduled medical contact in 
September.
The increase could be caused by GPs needing to see 
certain patients before giving a new prescription if they 
had not had a prescription recently. Evidence to support 
this is a post hoc observation that for children who had 
collected a prescription within the last 3 months prior to 
the start of the study, there was an increase in unsched-
uled contacts in September with 55.2% of patients in the 
Figure 2 Unscheduled medical contacts and prescriptions over time.
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intervention arm seeing their GP compared with 54.3% 
for controls. For patients whose last prescription was 
3–6 months prior to the start of the study, the difference 
between the arms was greater with 42.1% in the interven-
tion arm seeing their GP in September compared with 
39.7% for controls.
The way the unscheduled contacts were coded could 
have also impacted on the outcome. The interven-
tion increased prescription update and collection of a 
prescription for asthma was coded as an unscheduled 
medical contact.
A further explanation for the lack of effect of the 
intervention on unscheduled contacts in September is 
that September was too early to make an assessment of 
efficacy. Given that exposure to infections may take some 
time to have an impact on asthma symptoms in school-age 
children, it is possible that making the primary outcome 
period the first 4 weeks after returning to school was too 
soon to observe an effect of the intervention.
It is interesting that an effect in favour of the interven-
tion was demonstrated when the measurement period 
was extended both to December and to the following 
August. In the extended period, both the total number 
of contacts per child (ie, scheduled plus unscheduled) 
and unscheduled contacts were lower in the interven-
tion group than in the control over the extended study 
period (September–December 2013) and the full year 
(September 2013–August 2014), although only the effect 
Table 3 Analysis of prescription and scheduled contacts for August
Treatment arm* Treatment arm*
Intervention 
(%)
Control
(%) OR† 95% CI
Intervention
(mean)
Control
(mean)
Incidence 
ratio† 95% CI
Prescriptions 
  All children 16.5 12.6 1.43 1.24 to 1.64 0.17 0.13 1.31 1.17 to 1.48
  Preventer 17.3 13.4 1.41 1 23 to 1.63 0.18 0.14 1.30 1.16 to 1.47
Scheduled contacts 
  All children 14.3 13.9 1.13 0.84 to 1.52 0.17 0.16 1.17 1.06 to 1.29
  Preventer 14.8 14.4 1.14 0.84 to 1.54 0.18 0.17 1.17 1.06 to 1.29
*The proportions and means are simple summary statistics. 
†The ORs and incidence ratios with the corresponding CIs are from a formal statistical analysis allowing for covariates and the effect of 
clustering.
Figure 3 Unscheduled respiratory medical contacts.
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on the total number of medical contacts for the full year 
was statistically significant.
The effects on medical contacts, though small, are 
potentially clinically important given the effect the inter-
vention had on prescriptions. The expectation was an 
increase in prescription update would lead to a reduction 
in medical contacts. The results are in line with this expec-
tation. Moreover, the minimal cost associated with the 
intervention meant the intervention was found to have 
a high probability of being cost-saving overall. With such 
a relatively low cost intervention, £1.34 per child, and an 
average cost for an unscheduled surgery visit circa £50, an 
intervention would only need to reduce the number of 
contacts by three per year for an average practice with 85 
asthmatic children to be cost neutral. The evidence from 
the trial is that contacts are reduced by approximately0.6 
contacts per child in the 12 months after intervention or 
51 per year for an average practice of 85 children.
The economic analysis (which used data over a 
12-month period from August 2013 to July 2014) esti-
mated a mean cost saving across the base case of £36.07 
per child. So, although the study did not have a signif-
icant effect for the primary endpoint, the minimal cost 
associated with the intervention meant the intervention 
was found to have a high probability (96.3%) of being 
cost-saving overall, primarily due it its effect on reducing 
the total number of medical contacts over the following 
year. In the UK alone, there are over one million children 
with asthma. The intervention thus has the potential to 
provide health service savings if implemented.
The results were discussed with children with asthma 
and their parents at a PPI consultation event.21 At the 
event, attendees felt that the savings per child was an 
important result and suggested that the impact of the 
intervention could have been greater if it had been 
repeated over a number of years. The letter could then 
assist parents and children as they plan for the school 
return each year.
There is evidence of good user acceptability with over 
half the practices who responded to a survey reporting 
that they had repeated the intervention the year after the 
study.23 Once the intervention is set up for 1 year, the costs 
then associated with sending it out in subsequent years 
are less given that many of the school-age children with 
asthma will be the same from year to year.
There were methodological issues associated with the 
cluster randomised trial. Although there were 12 179 
children with asthma in the study, there were only 141 
GP practices, which was the unit of randomisation. With 
141 GP practices, there is a chance of random differences 
between the two intervention arms. Any random differ-
ences could be compounded by the fact that children 
with asthma and the common medical practice under-
taken to manage asthma would tend to be more alike 
within practices than between practices. This may affect 
the clinical outcomes.
The strengths of the study were that the intervention 
was evaluated in a relatively large trial population of 
children within a primary care setting within a single year. 
In addition, the procedures used in the study were the 
same as those that would be used in clinical practice and 
so implementation into routine care is straightforward.
The study had a highly efficient innovative study design 
that used routine data for all outcomes, and the delivery 
of the intervention was centrally automated through the 
CPRD. By our own estimation, a substantial six-figure 
sum is saved compared with a trial where GP practices 
would need to be visited to collect the data. There were 
additional practical advantages in using routine data. For 
example, the planning of data collection was relatively 
straightforward to schedule and the collection of base-
line data could be done retrospectively once practices 
had entered the trial.
This final strength of the trial is also a weakness. 
Using routine data made the assessment of unsched-
uled contacts within the trial difficult, especially for 
an intervention that increased initial medical activity 
through the collection of prescriptions. In this study, it 
would have been helpful for two additional questions 
to be asked to facilitate evaluation of the intervention: 
was the contact unscheduled? Was the contact respira-
tory related?
The study adds to the current literature by demon-
strating that an easy to implement intervention of a 
simple letter from a GP to the parents of a children 
with asthma can assist in the self-management of 
the condition by increasing prescription uptake and 
consequently reducing medical contacts. Over 90% of 
medical contacts are in a primary care setting and yet 
there is a paucity of evaluations in this setting. This 
has demonstrated that using routine data collected 
through the CPRD within a cluster randomised trial is 
feasible and has shown the advantages and disadvan-
tages of this approach.
COnClusIOns
The intervention succeeded in increasing the number of 
children collecting a prescription in August. The inter-
vention did not reduce unscheduled care as expected in 
September, which was the primary endpoint, although in 
the year following the intervention, it had a statistically 
significant, and potentially clinically important, effect on 
reducing total medical contacts. This is reflected in the 
health economic evaluation which, overall, showed that 
the intervention had a high probability of giving a cost 
saving.
With the evidence from the trial of an increase in 
August of both prescription collection and evidence of 
cost reduction practices may wish to implement the inter-
vention, particularly practices with high rates of unsched-
uled medical care.
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